List of Excipients in Branded Drug DICYCLOMINE HCL

« Back to Dashboard

Generic Drugs Containing DICYCLOMINE HCL

Company	Ingredient	NDC	Excipient
Nexus Pharmaceuticals LLC	dicyclomine hydrochloride	14789-010	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in DICYCLOMINE HCL?

# Of NDCs	Excipient
1	SODIUM CHLORIDE

Dicyclomine HCl Excipient Strategy and Commercial Opportunities

Last updated: October 15, 2026

Dicyclomine hydrochloride is an established anticholinergic used for functional bowel disorders, including irritable bowel syndrome. Its core drug substance has limited current patent protection, so commercial value depends on formulation execution, supply reliability, patient usability, and regulatory positioning. The strongest opportunities are palatable oral liquids, dose-flexible products, unit-dose packaging, and differentiated formulations that improve adherence without creating unnecessary clinical or regulatory risk.

What is the FDA status of dicyclomine hydrochloride?

Dicyclomine hydrochloride is FDA-approved for the treatment of functional bowel and irritable bowel syndrome symptoms in adults. The reference product is Bentyl, historically marketed by Aptalis Pharma and later associated with other commercial owners. FDA-approved dosage forms include oral capsules, tablets, oral solution, and intramuscular injection products, although commercial availability varies by manufacturer and market.

Attribute	Dicyclomine hydrochloride
Pharmacologic class	Anticholinergic, antispasmodic
Primary use	Functional bowel disorder and irritable bowel syndrome symptoms
Common oral strengths	10 mg and 20 mg
Oral dosage forms	Capsules, tablets, oral solution
Parenteral dosage form	Intramuscular injection
Reference product	Bentyl
FDA pathway for conventional generics	ANDA under section 505(j)
FDA pathway for novel delivery systems	Potentially 505(b)(2)
Current biologic or biosimilar exposure	None
Current patent-driven exclusivity	No meaningful current Orange Book patent barrier identified

The FDA label warns about anticholinergic effects, including dry mouth, blurred vision, urinary retention, tachycardia, and central nervous system effects. Dicyclomine is contraindicated in infants younger than six months because of reports of serious respiratory and neurologic adverse events. The product is also contraindicated in breastfeeding women under the U.S. label because of potential infant risk [1].

When does dicyclomine lose exclusivity?

Dicyclomine hydrochloride lost practical market exclusivity decades ago. The original drug and conventional dosage forms are genericized, and the commercial market is primarily supplied through multiple abbreviated new drug applications.

The relevant commercial distinction is between drug exclusivity and formulation differentiation:

Exclusivity category	Dicyclomine HCl position
Original small-molecule exclusivity	Expired
New chemical entity exclusivity	Expired
Conventional composition patents	Expired or commercially irrelevant
Orange Book formulation patents	No material current barrier identified
Method-of-use patents	No material current barrier identified for ordinary IBS use
Generic competition	Established
Formulation-specific future exclusivity	Possible through a genuinely novel product

A company developing a conventional 10 mg or 20 mg tablet should assume that the opportunity is a cost, supply, packaging, or patient-use competition rather than a patent-protected market. A novel delivery system could create a separate regulatory and commercial position, but the value would depend on clinical differentiation and the strength of the resulting claims.

What patents protect dicyclomine hydrochloride products?

Current U.S. patent protection is unlikely to block ordinary generic development of dicyclomine hydrochloride tablets, capsules, oral solutions, or intramuscular products. The central active pharmaceutical ingredient and legacy Bentyl dosage forms have been marketed for many years.

Orange Book status

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the controlling source for listed patents and exclusivity codes. Dicyclomine products should be reviewed by reference listed drug, dosage form, strength, and applicant because Orange Book entries can vary by product and may not reflect every patent relevant to a broader formulation strategy [2].

For a conventional generic, the expected filing route is an ANDA with a Paragraph III or Paragraph IV certification, depending on any listed patents associated with the selected reference product. If no unexpired listed patent applies, a Paragraph IV challenge is unnecessary. If an applicant identifies a listed patent that it believes is invalid, unenforceable, or not infringed, a Paragraph IV certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework [3].

Formulation and method-of-use patents

The more realistic patent opportunity is a new formulation, such as:

• A taste-masked oral solution
• A concentrated liquid with improved dose accuracy
• A sustained-release product
• A rapidly disintegrating tablet
• A multiparticulate sprinkle formulation
• A low-sugar or sugar-free product with improved palatability
• A unit-dose product with improved stability
• A novel combination product

A patent must claim a real technical distinction. Broad claims covering dicyclomine with routine excipients are vulnerable to obviousness challenges. Stronger claim sets would link the excipient system to measurable performance, such as improved chemical stability, reduced precipitation, reduced bitterness, controlled release, or a defined dissolution profile.

Which excipients are strategically relevant for dicyclomine HCl?

Excipient selection should follow the dosage form, target patient group, manufacturing platform, and regulatory pathway. Dicyclomine hydrochloride is a salt of a basic anticholinergic compound and is suitable for both solid and liquid oral dosage forms. The most important formulation variables are taste, dose uniformity, moisture control, dissolution, preservative burden, and manufacturing cost.

Oral tablets

A conventional immediate-release tablet can use a standard excipient architecture:

Formulation function	Candidate excipient classes
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Magnesium stearate, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants

For a low-dose product, content uniformity is a central development issue. Dicyclomine strength can be small relative to the tablet mass, so blending performance and segregation control matter more than simply selecting the lowest-cost filler.

Microcrystalline cellulose and lactose offer established processing performance. Mannitol can improve mouthfeel in orally disintegrating or chewable systems but may raise tablet weight and cost. Magnesium stearate is commercially common but requires controlled blending because over-lubrication can slow dissolution.

Hard capsules

Capsules permit rapid development and can reduce compression-related formulation work. Candidate excipients include lactose, microcrystalline cellulose, starch, colloidal silicon dioxide, and magnesium stearate.

Capsules are commercially attractive when the target market values low-cost generic supply and multiple strengths. They are less attractive for pediatric or dysphagia-focused products because they do not provide dose flexibility and may create swallowing barriers.

Oral solution

Oral liquids are the clearest excipient-led opportunity. Dicyclomine oral solution can support patients who cannot swallow tablets or capsules and can enable dose adjustment.

The formulation must control:

• Bitterness and throat irritation
• pH-dependent stability
• Microbial growth
• Precipitation during storage
• Dose uniformity after repeated use
• Container compatibility
• Preservative exposure
• Sugar and alcohol content

Candidate excipient categories include buffers, sweeteners, flavor systems, preservatives, chelating agents, viscosity modifiers, and solubilizers. A typical development screen could compare sucrose, sorbitol, glycerin, and high-intensity sweeteners; citrate or phosphate buffering systems; and approved preservative systems such as parabens or benzoate-based systems, subject to compatibility and labeling requirements.

Taste masking should not rely solely on higher sweetness. Anticholinergic bitterness can persist after sweetener optimization. Flavor selection, pH adjustment, viscosity, and mouth-coating polymers should be evaluated together. A sugar-free, alcohol-free, low-volume formulation could create a stronger commercial position than a conventional syrup.

Orally disintegrating tablets

An orally disintegrating tablet could target adults with swallowing difficulty and patients seeking convenient administration. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers are relevant excipient classes.

The main technical risk is that rapid disintegration increases exposure of dicyclomine to taste receptors. A successful product would need a credible taste-masking system, not simply a fast-disintegrating matrix. Packaging must also protect against moisture because many orally disintegrating systems are more hygroscopic and mechanically fragile than standard tablets.

Injectable product

The injectable product requires sterile manufacturing and a much higher quality-control burden. Excipient priorities include tonicity, pH adjustment, particulate control, container closure integrity, and compatibility with the selected vial or ampule.

The injectable market is narrower than the oral market because of administration requirements and the availability of oral alternatives. A preservative-free, ready-to-use presentation could have institutional value, but the opportunity is limited by sterile manufacturing costs and the established nature of the product.

What commercial opportunities exist for dicyclomine excipients?

1. Sugar-free and alcohol-free oral solution

A sugar-free and alcohol-free oral solution could address patients with diabetes, children outside the contraindicated infant population, older adults, and patients who prefer liquid administration. The commercial case depends on:

• Acceptable taste
• Accurate dosing device
• Low dosing volume
• Long in-use stability
• Broad pharmacy distribution
• Competitive pricing

The product should be packaged with an oral syringe rather than relying only on a household teaspoon. Dose-measuring errors are a practical weakness of many legacy liquid products.

2. Unit-dose liquid packaging

Unit-dose cups, stick packs, or premeasured oral syringes could target hospitals, long-term-care facilities, correctional health systems, and specialty pharmacies. The value comes from dose accuracy, reduced cross-contamination, and simplified medication administration.

The main barriers are packaging cost, filling-line compatibility, and the need to demonstrate stability in the final container. A unit-dose product would need a clear cost advantage over multidose bottles in institutional purchasing.

3. Low-cost, robust immediate-release tablets

The largest volume opportunity is still a reliable conventional tablet or capsule. A manufacturer can compete through:

• High-yield direct compression
• Reduced excipient count
• Domestic or dual-source excipient supply
• Shorter manufacturing cycle time
• Strong moisture protection
• Consistent dissolution across batches

For a low-price generic, excipient simplification has greater value than an expensive patented delivery system unless the product has a clear reimbursement or channel advantage.

4. Orally disintegrating or chewable dosage form

A taste-masked orally disintegrating or chewable product could differentiate from standard tablets. Commercial demand would likely be concentrated in patients with dysphagia, older adults, and selected outpatient settings.

The product should not be positioned for infants because dicyclomine is contraindicated in patients younger than six months. Pediatric-oriented branding would require careful age restrictions and safety communication.

5. Private-label and contract manufacturing

Dicyclomine is suitable for private-label generic portfolios because the active ingredient is established and the core dosage forms are conventional. Opportunities exist for:

• Regional pharmacy chains
• Telehealth pharmacies
• Hospital purchasing organizations
• Long-term-care distributors
• International generic companies
• Contract development and manufacturing organizations

The most defensible CDMO offering would combine active sourcing, analytical method transfer, liquid formulation capability, and small-batch packaging rather than provide only tableting capacity.

How strong is the dicyclomine hydrochloride patent estate?

The patent estate is weak for conventional products and potentially moderate for a genuinely differentiated formulation.

Patent strategy	Expected strength
New patent on dicyclomine HCl itself	Very weak because of long public use
Routine tablet excipient combination	Weak
Standard oral solution	Weak to moderate
Demonstrated taste-masking system	Moderate if supported by comparative data
Novel sustained-release system	Moderate to strong if technically differentiated
Unit-dose packaging patent	Usually weak as a standalone barrier
Stability-enhancing formulation	Moderate if data show unexpected improvement
Combination product	Depends on clinical and formulation distinctiveness

Patent strength should be supported by comparative examples, not ingredient lists. Useful evidence includes accelerated stability, dissolution comparisons, taste-panel results, precipitation testing, preservative effectiveness, and pharmacokinetic data where release characteristics differ.

Which companies are challenging dicyclomine products?

The market is supplied primarily by generic manufacturers and distributors rather than by companies pursuing branded patent litigation. Dicyclomine generic competition can include manufacturers such as Hikma, Mylan or Viatris, Teva, Dr. Reddy’s, Lannett, and other ANDA holders, depending on current product availability and market channel.

Because supplier participation changes over time, a competitive review should distinguish among:

• Approved ANDA holders
• Current commercial suppliers
• Products listed as available in pharmacy channels
• Products with temporary or permanent discontinuation reports
• Suppliers serving hospitals versus retail pharmacies

A high ANDA count does not guarantee active competition. Dicyclomine pricing can be affected by supply interruptions, contract concentration, API sourcing, and pharmacy benefit formulary decisions.

What generic entry risks exist?

Generic entry risk is already realized for conventional dicyclomine products. The relevant business risks are supply and substitution risks rather than an initial loss of exclusivity.

Risk profile by product type

Product type	Generic risk	Main commercial issue
10 mg or 20 mg tablet	High	Price compression
Hard capsule	High	Limited differentiation
Conventional oral solution	High to moderate	Taste and availability
Sugar-free liquid	Moderate	Formulation and packaging execution
Orally disintegrating tablet	Moderate	Taste masking and market adoption
Sustained-release product	Lower initially	Clinical and regulatory burden
Ready-to-use injection	Moderate	Sterile manufacturing and institutional demand

A differentiated product may receive some protection through formulation patents, regulatory exclusivity for a qualifying new application, or commercial contracts. Those protections are generally narrower than the original drug’s market and should not be treated as equivalent to broad molecule exclusivity.

How does dicyclomine compare with competing antispasmodics?

Dicyclomine competes with other prescription and over-the-counter approaches to abdominal cramping and irritable bowel symptoms. Competition includes hyoscyamine products, peppermint oil products, dietary interventions, laxatives, antidiarrheals, and disease-specific treatments for constipation-predominant or diarrhea-predominant IBS.

Product category	Dicyclomine position
Anticholinergic antispasmodic	Established prescription option
Peppermint oil	Nonprescription or supplement-oriented alternative in some markets
Hyoscyamine	Prescription anticholinergic competitor
IBS-C therapies	Treat constipation mechanism rather than general spasm
IBS-D therapies	Treat diarrhea-predominant disease features
Behavioral and dietary management	Non-drug alternatives
Combination products	Potential future differentiation route

Dicyclomine’s limitations include systemic anticholinergic adverse effects and restricted use in very young patients. A formulation that improves administration does not eliminate the active ingredient’s pharmacologic safety constraints.

What regulatory strategy fits a new dicyclomine formulation?

A conventional tablet, capsule, or oral solution that demonstrates pharmaceutical equivalence to an approved reference product generally fits the ANDA pathway. A product with a materially different dosage form, release profile, route, or clinical use may require a 505(b)(2) application.

The regulatory decision should be based on the intended claim:

• Same active ingredient, same route, same dosage form: likely ANDA
• Different release profile: possible 505(b)(2)
• New delivery technology: possible 505(b)(2)
• New combination: potentially 505(b)(2) or other pathway
• New indication: may require additional clinical evidence

Excipient changes must be assessed for safety, performance, bioequivalence, product quality, and labeling impact. Oral solutions may avoid some dissolution problems but still require stability, preservative effectiveness, microbial limits, and dose-uniformity controls.

What manufacturing and IP barriers affect commercial launch?

The API is not expected to be the principal barrier. More important barriers include:

• Reliable API sourcing and impurity control
• Low-dose blend uniformity
• Taste-masking reproducibility
• Liquid preservative effectiveness
• Moisture-sensitive packaging
• Sterile filling for injection
• Excipient qualification and dual sourcing
• Stability in commercial packaging
• Bioequivalence for modified-release products
• Freedom-to-operate review for novel delivery systems

Geographic strategy should account for differences in approved excipients, permitted preservatives, labeling requirements, and reference-product standards. A formulation designed for the U.S. market may require changes for Europe, Japan, or emerging markets because excipient acceptability and product classification differ.

What is the commercial outlook for dicyclomine hydrochloride?

Dicyclomine is a mature, price-sensitive drug with limited molecule-level IP value. The best near-term commercial opportunities are operational and formulation-based:

1. A low-cost, reliably supplied tablet or capsule.
2. A sugar-free, alcohol-free oral solution with strong palatability.
3. A dose-accurate unit-dose liquid for institutional use.
4. A moisture-protected orally disintegrating tablet.
5. A contract manufacturing platform for generic portfolio owners.

Revenue exposure should be assessed through prescription volume, net price, channel mix, and supply continuity. Public company filings generally do not isolate dicyclomine revenue, so product-level revenue estimates should not be inferred from total company sales.

Key Takeaways

• Dicyclomine hydrochloride has no meaningful current molecule-level exclusivity in the conventional U.S. market.
• Generic competition is established for tablets, capsules, oral solutions, and injectable products.
• Excipient strategy matters most for taste, dose uniformity, liquid stability, moisture protection, and patient usability.
• Sugar-free, alcohol-free oral liquids and unit-dose packaging offer the clearest differentiation opportunities.
• Conventional excipient combinations are unlikely to support strong patent protection without comparative technical data.
• A sustained-release, orally disintegrating, or other novel formulation may support a 505(b)(2) strategy, but clinical and bioequivalence requirements increase.
• The commercial market is driven more by supply reliability, manufacturing efficiency, pharmacy access, and formulation convenience than by patent exclusivity.

FAQs

Is dicyclomine hydrochloride still patent protected?

Conventional dicyclomine hydrochloride products are not expected to have meaningful current U.S. patent protection. Any active listed patent must be evaluated against the specific reference product and dosage form in the Orange Book.

What is the best excipient for dicyclomine oral solution?

No single excipient is optimal. A successful oral solution normally requires a coordinated system of sweetener, flavor, buffer, preservative, viscosity modifier, and packaging. Taste masking and long-term stability should determine the final composition.

Can dicyclomine be developed as a sugar-free product?

Yes. A sugar-free oral solution or orally disintegrating tablet is technically feasible, subject to stability, palatability, preservative, dose-uniformity, and regulatory requirements.

Does dicyclomine have biosimilar competition?

No. Dicyclomine hydrochloride is a small-molecule drug, so competition occurs through generic drug pathways rather than biosimilar approval.

Is a dicyclomine combination product commercially attractive?

Potentially, but the product would need a clear therapeutic rationale, compatible dosing, regulatory support, and evidence that the combination improves treatment value over separate administration. A combination product would not automatically avoid generic or patent competition.

References

1. U.S. Food and Drug Administration. (2023). Bentyl (dicyclomine hydrochloride) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. U.S. Food and Drug Administration. (1997). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and postapproval changes. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. https://www.fda.gov/regulatory-information/search-fda-guidance-documents